Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| MiroMatrix Medical Inc | MIRO | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3.39 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.39 | 3.39 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.906499 - 3.53 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 3.39 | USD |
MiroMatrix Medical Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| US$ 92.95M | - | - | - | -4.30 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
MiroMatrix Medical News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MIRO Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 1.02 | 3.53 | 0.9603 | 3.30 | 318,110 | 2.37 | 232.35% |
| 1 Year | 1.28 | 3.53 | 0.906499 | 2.73 | 95,184 | 2.11 | 164.84% |
| 3 Years | 12.00 | 16.5212 | 0.906499 | 4.40 | 63,686 | -8.61 | -71.75% |
| 5 Years | 12.00 | 16.5212 | 0.906499 | 4.40 | 63,686 | -8.61 | -71.75% |
MiroMatrix Medical Description
| Miromatrix Medical Inc is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients' lives. It has developed a proprietary perfusion technology platform for bioengineering organs that will scale to address the shortage of available human organs. Its initial development focus is on human livers and kidneys and has demonstrated the ability to bioengineer these organs with functional vasculature and important organ function in preclinical studies. |
